Rethinking the application of pemetrexed for patients with renal impairment: a pharmacokinetic analysis
N de Rouw, RJ Boosman, ADR Huitema… - Clinical …, 2021 - Springer
Background Pemetrexed is used for the treatment for non-small cell lung cancer and
mesothelioma. Patients with renal impairment are withheld treatment with this drug as it is …
mesothelioma. Patients with renal impairment are withheld treatment with this drug as it is …
Population pharmacokinetic study of pemetrexed in chinese primary advanced non-small cell lung carcinoma patients
P Cao, W Guo, J Wang, S Wu, Y Huang… - Frontiers in …, 2022 - frontiersin.org
The purposes of this study were to identify physiological and genetic factors that contributed
to variability of pemetrexed (PEM) exposure and to optimize the dosing regimens for …
to variability of pemetrexed (PEM) exposure and to optimize the dosing regimens for …